$ News

Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team

Sanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal

Sanofi concludes Blueprint Medicines acquisition

Press Release: Sanofi completes acquisition of Blueprint Medicines

Press Release: Sanofi announces extension of Blueprint tender offer

Blueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic Mastocytosis

Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

Sanofi to acquire Blueprint Medicines, Boeing upgrade

Sanofi to expand immunology offerings with Blueprint Medicines

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

Sanofi to Acquire Blueprint Medicines for up to $9.5 Billion to Expand Immunology Portfolio

Sanofi to acquire Blueprint for up to $9.5B

‘Stay Invested’: Wells Fargo Suggests 2 Stocks to Ride the Market Recovery

Blueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates

Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings